Destiny Pharma : Interim results for the six months ended 30 June 2023 -September 20, 2023 at 02:29 am EDT

Destiny Pharma plc



Interim results for the six months ended 30 June 2023


Active discussions with potential partners for XF-73 nasal supported by new...

Related Keywords

United States ,Brighton ,Brighton And Hove ,United Kingdom ,Mexico ,Canada ,America ,Debra Barker ,Nigel Birks Harriet ,Geoff Nash George Dollemore ,Chris Tovey ,Nigel Rudd ,Shaun Claydon ,Investor Meet Company ,Cavendish Capital Markets Limited Nominated Adviser ,Sebela Pharmaceuticals ,National Institute ,Powerscourt Group ,Destiny Pharma ,North America ,Chief Executive Officer ,Sir Nigel Rudd ,Microbiology Spectrum ,Infection Control ,Infectious Diseases ,Fungal Biology ,Non Executive Director ,Senior Independent Director ,Adam Michael ,Ollie Simmonds ,Capital Markets Limited ,Nominated Adviser ,Joint Broker ,George Dollemore ,Harriet Ward ,James Thomas ,Markets ,